Micro
Emerging
Active
Hims & Hers Health, Inc. analysis
New narrative with limited coverage — still forming.
Score
0.3
Velocity
▲ 0.0
Articles
4
Sources
3
Sentiment Timeline
Event Timeline
Related Articles
🤖
AI Overview
On April 25, Hims & Hers Health (HIMS) stock plummeted 15% in premarket trading following the company's first-quarter earnings report. The telehealth company posted a net loss of $92 million and sales that missed Wall Street expectations, primarily due to increased costs associated with its pivot to branded weight-loss medications.
The sell-off in HIMS stock negatively impacted the broader telehealth sector, with shares of competitors like Teladoc Health (TDOC) and Amwell (AMWL) also declining. The market is repricing HIMS' valuation, reflecting concerns about the company's ability to control costs and achieve profitability.
Investors should closely monitor HIMS' next earnings report, scheduled for August 11, to assess the company's progress in managing expenses and growing its weight-loss medication business. Additionally, any updates on HIMS' regulatory approvals for new products could significantly influence the stock's performance.
The sell-off in HIMS stock negatively impacted the broader telehealth sector, with shares of competitors like Teladoc Health (TDOC) and Amwell (AMWL) also declining. The market is repricing HIMS' valuation, reflecting concerns about the company's ability to control costs and achieve profitability.
Investors should closely monitor HIMS' next earnings report, scheduled for August 11, to assess the company's progress in managing expenses and growing its weight-loss medication business. Additionally, any updates on HIMS' regulatory approvals for new products could significantly influence the stock's performance.
AI Overview as of May 12, 2026
Timeline
Last UpdatedMay 03, 2026